You are here

Home Administration of NivestimTM in the Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia

Last updated on May 10, 2018

FOR MORE INFORMATION
Study Location
Office of Manfred Welslau
Aschaffenburg, , 63739 Germany
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Non-Interventional Study
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male and female patients ≥ 18 years

- Declaration of informed consent signed by patient

- Patients with a solid tumour or with a malignant haematological tumour

- Patients who have been prescribed cytotoxic chemotherapy, irrespective of current
cycle

- GCSF-naïve patients or patients pre-treated with GCSF who received no GCSF in the last
three months before enrolment

- Patients starting primary prophylactic treatment using NivestimTM either to shorten
the duration of a neutropenia or to prevent the occurrence of chemotherapy-induced FN

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients with chronic myeloid leukaemia (CML) or with myelodysplastic syndrome (MDS)

- Patients who are hypersensitive to one of the excipients of NivestimTM

- Patients not undergoing chemotherapy

- Patients being treated curatively or as secondary prophylaxis with G-CSF

NCT02956967
Pfizer
Completed
Home Administration of NivestimTM in the Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Non-Interventional Study
NCT02956967
All Genders
18+
Years
Multiple Sites
Methodology Study
NCT00716521
All Genders
18+
Years
New Haven, Connecticut
Healthy Volunteer Study
NCT03270878
All Genders
18+
Years
New Haven, Connecticut
Home Administration of NivestimTM in the Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia
Home Administration Of Nivestimtm In The Primary Prophylaxis Of Chemotherapy-induced Febrile Neutropenia Non-interventional, Observational, Prospective Study Short Name: Home
Non-interventional, non-comparative, national, multi-site, single-arm prospective observational study to investigate home administration of Nivestim in the primary prophylaxis of chemotherapy-Induced febrile neutropenia
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Adults undergoing cytotoxic chemotherapy treated prophylactically with NivestimTM in order to reduce the duration of neutropenia and to reduce the incidence of chemotherapy-induced FN.
Non-Interventional Study
Other: Overall satisfaction questionnaires of home use of Nivestim
Patients receiving Nivestim
Intervention: Other: Overall satisfaction questionnaires of home use of Nivestim
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
171
December 12, 2016
December 12, 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male and female patients ? 18 years
  • Declaration of informed consent signed by patient
  • Patients with a solid tumour or with a malignant haematological tumour
  • Patients who have been prescribed cytotoxic chemotherapy, irrespective of current cycle
  • GCSF-naïve patients or patients pre-treated with GCSF who received no GCSF in the last three months before enrolment
  • Patients starting primary prophylactic treatment using NivestimTM either to shorten the duration of a neutropenia or to prevent the occurrence of chemotherapy-induced FN

Exclusion Criteria:

  • Patients with chronic myeloid leukaemia (CML) or with myelodysplastic syndrome (MDS)
  • Patients who are hypersensitive to one of the excipients of NivestimTM
  • Patients not undergoing chemotherapy
  • Patients being treated curatively or as secondary prophylaxis with G-CSF
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
 
NCT02956967
ZOB-NIV-1504
C1121004 ( Other Identifier: Alias Study Number )
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
March 2017

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now